Inclusion Criteria:

- Histologically or cytologically confirmed hepatocellular carcinoma

- Measurable disease

- Life expectancy greater than 3 months

- ECOG performance status 0 or 1

- BCLC Stage C disease

- Lab values must be within limits outlined in protocol

- Child-Pugh score
- CLIP score 0-3

- Must agree to use adequate contraception

Exclusion Criteria:

- Chemotherapy or radiotherapy within 4 weeks prior to entering study or not recovered
from adverse events due to agents administered more than 4 weeks earlier

- Receiving any other investigational agent

- Known brain metastases unless treated and radiographically and clinically stable
without steroid or anticonvulsant medications for at least 4 weeks prior to first
dose of STA-9090

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to STA-9090

- Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable
disease

- Major surgery within 4 weeks prior to first dose of STA-9090

- Poor venous access for study drug administration or would require a peripheral or
central indwelling catheter for study drug administration

- History of severe allergic or hypersensitivity reactions to excipients (e.g.,
Polyethylene glycol [PE] 300 and Polysorbate 80)

- Baseline QTc > 450 msec or previous history of QT prolongation while taking other
medications

- Ventricular ejection fraction
- Treatment with chronic immunosuppressants

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant or breast-feeding

- History of a different malignancy unless disease-free for at least 5 years and deemed
by the investigator to be at low risk for recurrence.

- HIV-positive individuals on combination antiretroviral therapy